- Home
- TWST
as 07-03-2025 3:42pm EST
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.8B | IPO Year: | 2018 |
| Target Price: | $49.10 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.12 - $60.90 | Next Earning Date: | 08-01-2025 |
| Revenue: | $347,680,000 | Revenue Growth: | 25.30% |
| Revenue Growth (this year): | 22.58% | Revenue Growth (next year): | 17.71% |
Stock Insider Trading Activity of Twist Bioscience Corporation (TWST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leproust Emily M. | TWST | Chief Executive Officer | Jun 20 '25 | Sell | $35.76 | 1,678 | $59,996.89 | 645,782 | |
| Green Paula | TWST | SVP of Human Resources | Jun 20 '25 | Sell | $35.76 | 292 | $10,440.46 | 127,603 | |
| Cho Dennis | TWST | See Remarks | Jun 20 '25 | Sell | $35.76 | 230 | $8,223.65 | 104,737 | |
| Cho Dennis | TWST | See Remarks | Jun 16 '25 | Sell | $33.48 | 94 | $3,146.65 | 104,737 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Jun 6 '25 | Sell | $31.75 | 2,170 | $68,897.50 | 645,782 | |
| Green Paula | TWST | SVP of Human Resources | Jun 6 '25 | Sell | $31.75 | 853 | $27,082.75 | 127,603 | |
| Cho Dennis | TWST | See Remarks | Jun 6 '25 | Sell | $31.75 | 257 | $8,159.75 | 104,737 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Jun 6 '25 | Sell | $31.75 | 225 | $7,143.75 | 49,966 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | May 23 '25 | Sell | $27.73 | 839 | $23,263.79 | 49,966 | |
| Leproust Emily M. | TWST | Chief Executive Officer | May 21 '25 | Sell | $29.75 | 2,802 | $83,351.09 | 645,782 |
Latest Twist Bioscience Corporation News
TWST Breaking Stock News: Dive into TWST Ticker-Specific Updates for Smart Investing
Insider Monkey
11 days ago
Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions
Simply Wall St.
18 days ago
Here's Why We're Not At All Concerned With Twist Bioscience's (NASDAQ:TWST) Cash Burn Situation
MT Newswires
a month ago
Twist Bioscience Expands Element Biosciences Partnership for End-to-End NGS Tools
Business Wire
a month ago
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
Business Wire
2 months ago
Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference
Business Wire
2 months ago
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insider Monkey
2 months ago
Twist Bioscience Corporation (TWST): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential
MT Newswires
2 months ago
Twist Bioscience, Ginkgo Bioworks Renegotiate Contract for DNA Technology, Assets
Compare TWST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TWST Twist Bioscience Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.